You are here

IGF OT IGF SBIR PHASE I TOPIC CTDNA DIAGNOSTIC ENABLED BY MAGNETIC AUTOMATION ASSAYS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 261201600036C-0-0-0
Agency Tracking Number: N43CA160036
Amount: $275,261.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: N/A
Timeline
Solicitation Year: 2016
Award Year: 2016
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
942 RICH PL
MOUNTAIN VIEW, CA 94040-2477
United States
DUNS: 966369048
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 ALEXIS HUDAK
 (408) 505-9232
 aihua.fu@gmail.com
Business Contact
 ALEXIS HUDAK
Phone: (408) 505-9232
Email: aihua.fu@gmail.com
Research Institution
N/A
Abstract

Circulating tumor DNA ctDNA is a promising biomarker for noninvasive diagnostic prognostic and follow up tests for cancer However the relatively low quantity of ctDNA and the rare cancer mutations within large excess of wild type DNAs have presented many challenges for its application in the clinic The goal of the research is to develop our magnetic nanobeads and highly fluorescent magnetic nanoparticles enabled automatic sample preparation and diagnostic assay technology for ctDNA diagnostics Our magnetic ctDNA extraction technology offers higher yield and quality of extracted ctDNA compared to maket standard our magnetic DNA sizing beads ensure DNA library with higher yield and cleanness for better NGS data the magnetic automation will improve assay throughput consistency and save cost and the HFMN gene mutation detection assay provides the opportunity for faster and more economic mutation detection for physician to make discrete treatment management The ctDNA diagnostics to be developed through this project can be applied for roughly of breast cancer patients who were subtyped ER Her and treated with endocrine therapy at time of relapse for physicians to make personalized treatment decisions that can lead to more effective outcome Once successfully established our ctDNA diagnostic platform can be expanded to multiple other cancer types using circulating nucleic acids as reliable biomarkers for earlier cancer detection patient stratification and serial monitoring of cancer treatment and improving treatment for millions of cancer patients

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government